LUMIGAN^®

LUMIGAN^® is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers):^1–3

1. LUMIGAN^® (bimatoprost ophthalmic solution 0.01%). Summary of Product Characteristics. 2022.
2. LUMIGAN^® (bimatoprost ophthalmic solution 0.03% MD). Summary of Product Characteristics. 2022.
3. LUMIGAN^® (bimatoprost ophthalmic solution 0.03% UD). Summary of Product Characteristics. 2022.